{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:33:07Z","timestamp":1747164787460,"version":"3.40.5"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jhep.2019.01.011","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T07:38:59Z","timestamp":1549093139000},"page":"1028-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reply to: \u201cProphylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?\u201d"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-0716","authenticated-orcid":false,"given":"Paolo","family":"Angeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5440","authenticated-orcid":false,"given":"Mauro","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.01.011_b0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.01.011_b0010","unstructured":"Europen Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2018;44."},{"key":"10.1016\/j.jhep.2019.01.011_b0015","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","article-title":"Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone","volume":"175","author":"Lee","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2019.01.011_b0020","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jacc.2018.06.067","article-title":"Fluoroquinolone and the risk of aortic dissection","volume":"72","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2019.01.011_b0025","first-page":"1","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: Nationwide cohort study","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2019.01.011_b0030","unstructured":"European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2015."},{"key":"10.1016\/j.jhep.2019.01.011_b0035","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/apt.14361","article-title":"Rifaximin for the prophylaxis of spontaneous bacterial peritonitis: a systematic review","volume":"46","author":"Goel","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.01.011_b0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/jhep.2002.30082","article-title":"Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis","volume":"35","author":"Fern\u00e1ndez","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.011_b0045","article-title":"Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin","author":"Marciano","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.01.011_b0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2036.2005.02366.x","article-title":"Norfloxacin decreases bacterial adherence of quinolone-resistant strains of Escherichia coli isolated from patients with cirrhosis","volume":"21","author":"Gasc\u00f3n","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.01.011_b0055","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2018.08.026","article-title":"Effects of long-term norfloxacin therapy in patients with advanced cirrhosis","volume":"155","author":"Moreau","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.01.011_b0060","article-title":"Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide","author":"Piano","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.01.011_b0065","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.1840120416","article-title":"Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial","volume":"12","author":"Gin\u00e9s","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.01.011_b0070","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fern\u00e1ndez","year":"2007","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819300236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819300236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T01:01:03Z","timestamp":1556586063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819300236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0168827819300236"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.01.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: \u201cProphylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.12.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}